Full-Text Search:
Home|About CNKI|User Service|中文
Add to Favorite Get Latest Update

Thalidomide Combined with MP Regimen as Initial Therapy for 23 Cases with Multiple Myeloma

LIANG Min,TIAN Juan(The First Affiliated Hospital of Jishou University,Jishou 416000,China)  
[Purpose] To investigate the response and toxicity of thalidomide combined with MP regimen as initial therapy for multiple myeloma.[Methods] From Feb 2004 to Jan 2007,47 cases with untreated multiple myeloma were randomly divided into treatment group(n=23)and control group(n=24).Patients in both growps received MP regimen for 6~8 cycles.In addition,patients in treatment group received thalidomide oral administration at the same time.[Results] The overall response rate in treatment group and in control group were 78.3% and 50.0%(P=0.044)respectively.The progression free survival at 2-year,3-year and median progression free survival in treatment group and in control group were 55.9% vs 45.8%,21.0% vs 4.2% and 27 months vs 23 months(P=0.048).The overall survival at 2-year,3-year and median overall survival in treatment group and in control group were 86.5% vs 83.3%,73.7% vs 48.4% and 43 months vs 33 months(P=0.039).The incidence of hematologic toxicity and numbness of extermity in treatment group were higher than that in control group(P0.05).[Conclusions] Thalidomide combined with MP regimen can improve the progression free survival and overall survival for initial treated patients with multiple myeloma,and the toxicity is tolerable.
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
©CNKI All Rights Reserved